Flamel Technologies S.A. Given Consensus Rating of “Buy” by Brokerages (NASDAQ:FLML)
Shares of Flamel Technologies S.A. (NASDAQ:FLML) have been given an average rating of “Buy” by the eight analysts that are presently covering the company, American Banking News reports. Eight analysts have rated the stock with a buy recommendation, The average 12-month price target among analysts that have issued a report on the stock in the last year is $17.90.
Shares of Flamel Technologies S.A. (NASDAQ:FLML) traded up 0.90% on Friday, hitting $13.45. 40,430 shares of the company’s stock traded hands. Flamel Technologies S.A. has a 1-year low of $5.30 and a 1-year high of $15.75. The stock has a 50-day moving average of $14.00 and a 200-day moving average of $11.93. The company’s market cap is $514.7 million.
Flamel Technologies S.A. (NASDAQ:FLML) last posted its quarterly earnings results on Tuesday, July 29th. The company reported ($0.13) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.08) by $0.05. The company had revenue of $8.10 million for the quarter, compared to the consensus estimate of $9.92 million. During the same quarter in the prior year, the company posted ($1.29) earnings per share. Analysts expect that Flamel Technologies S.A. will post $-0.01 EPS for the current fiscal year.
Several analysts have recently commented on the stock. Analysts at Leerink Swann initiated coverage on shares of Flamel Technologies S.A. in a research note on Friday. They set an “outperform” rating and a $22.00 price target on the stock. Analysts at Zacks upgraded shares of Flamel Technologies S.A. from a “neutral” rating to an “outperform” rating in a research note on Tuesday, July 15th. They now have a $16.20 price target on the stock.
Flamel Technologies SA has a pipeline of niche specialty pharmaceutical products. The Company’s drug delivery platforms are focused on developing safer, more efficacious formulations of drugs to address unmet medical needs.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.